SecBot SecBot
SECBOTREPLAY Home › Report › ANIK

ANIK · Anika Therapeutics filed a second supplement to its proxy statement…

Anika Therapeutics, Inc. · DEFA14A filed Jun 8, 2026 at 09:25 ET

At the news

NEUTRALIMPACT 4/10

DEFA14A filed Jun 8, 2026 at 09:25 ET

Anika Therapeutics filed a second supplement to its proxy statement responding to ISS's unfavorable recommendation on Proposal 4 (equity incentive plan amendment). The board reduced the requested new share increase from 475,000 to 350,000 shares, lowering estimated dilution from ~29.40% to ~24.88%, and is now seeking approval of a 'Revised Seventh Amended Plan' capping total authorized shares at 6,110,000. The matter will be voted on at the June 18, 2026 annual meeting.

  • Board cut requested new shares from 475,000 to 350,000 after ISS flagged excessive dilution (estimated 29.40% fully diluted)
  • Revised plan would increase total shares reserved from 5,760,000 to 6,110,000, reducing estimated dilution to ~24.88%
  • Company noted ~$3.0 million in annualized savings from recent restructuring actions to support disciplined equity usage
  • Three-year average burn rate is 3.92% per fiscal years 2023-2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access